Literature DB >> 8357031

Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program.

A Tibben1, P G Frets, J J van de Kamp, M F Niermeijer, M Vegter-van der Vlis, R A Roos, G J van Ommen, H J Duivenvoorden, F Verhage.   

Abstract

We studied the baseline attitudes, prior to testing, of 70 applicants at risk for Huntington disease (HD) and their partners in the Dutch presymptomatic DNA-testing program. Two thirds of the applicants were female; 36% already had children. The main reason (60%) for undertaking the test was for family planning. Other reasons were either to reduce uncertainty (43%) or to obtain certainty (38%). Partners of applicants stated that planning for the future was for them the most important reason (76%). Significantly more at-risk females (42%) than males (16%) anticipated an unfavorable test outcome. Quite remarkably, most applicants and partners denied that a positive result might have adverse effects on either personal mood, quality of life, or marriage. Only a few did not expect that a favorable result would induce relief. The eventual outcome of the test was expected to enable applicants to gain control over their future, whatever the results. Hence, we propose that the applicants form a self-selected group, based on their expectation that they will not be emotionally affected by either result.

Entities:  

Mesh:

Year:  1993        PMID: 8357031     DOI: 10.1002/ajmg.1320480105

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  24 in total

1.  Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.

Authors:  L N Lodder; P G Frets; R W Trijsburg; E J Meijers-Heijboer; J G Klijn; H J Duivenvoorden; A Tibben; A Wagner; C A van der Meer; P Devilee; C J Cornelisse; M F Niermeijer
Journal:  J Med Genet       Date:  1999-12       Impact factor: 6.318

2.  More appreciation of life or regretting the test? Experiences of living as a mutation carrier of Huntington's disease.

Authors:  Anette Hagberg; The-Hung Bui; Elisabeth Winnberg
Journal:  J Genet Couns       Date:  2010-09-28       Impact factor: 2.537

3.  Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup.

Authors:  A C DudokdeWit; A Tibben; H J Duivenvoorden; M F Niermeijer; J Passchier
Journal:  J Med Genet       Date:  1998-09       Impact factor: 6.318

4.  Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing.

Authors:  Caroline Santa Maria Rodrigues; Viviane Ziebell de Oliveira; Gabriela Camargo; Claudio Maria da Silva Osório; Raphael Machado de Castilhos; Maria Luiza Saraiva-Pereira; Lavínia Schuler-Faccini; Laura Bannach Jardim
Journal:  J Genet Couns       Date:  2011-06-30       Impact factor: 2.537

5.  Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease.

Authors:  A Tibben; M Stevens; G M de Wert; M F Niermeijer; C M van Duijn; J C van Swieten
Journal:  J Med Genet       Date:  1997-01       Impact factor: 6.318

6.  Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease.

Authors:  Noelle E Carlozzi; David S Tulsky
Journal:  J Health Psychol       Date:  2012-03-16

Review 7.  Predictors of genetic testing decisions: a systematic review and critique of the literature.

Authors:  Kate Sweeny; Arezou Ghane; Angela M Legg; Ho Phi Huynh; Sara E Andrews
Journal:  J Genet Couns       Date:  2014-04-11       Impact factor: 2.537

8.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

9.  Problems assessing uptake of Huntington disease predictive testing and a proposed solution.

Authors:  Roslyn J Tassicker; Betty Teltscher; M Kaye Trembath; Veronica Collins; Leslie J Sheffield; Edmond Chiu; Lyle Gurrin; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2008-07-30       Impact factor: 4.246

10.  Withdrawal from genetic counselling for cancer.

Authors:  Eveline Bleiker; Gea Wigbout; Anja van Rens; Senno Verhoef; Laura Van't Veer; Neil Aaronson
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.